Get the Stockscreener App
5.01
0.20%
-0.010
Pre-market:
4.99
-0.02
-0.40%
Lisata Therapeutics Inc stock is traded at $5.01, with a volume of 17,294.
It is down -0.20% in the last 24 hours and up +14.12% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$5.02
Open:
$5.01
24h Volume:
17,294
Relative Volume:
0.11
Market Cap:
$45.25M
Revenue:
$170.00K
Net Income/Loss:
$-16.59M
P/E Ratio:
-2.6213
EPS:
-1.9113
Net Cash Flow:
$-15.98M
1W Performance:
+0.00%
1M Performance:
+14.12%
6M Performance:
+111.84%
1Y Performance:
+113.86%
1-Day Range:
$5.01
$5.03
1-Week Range:
$5.00
$5.04
52-Week Range:
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
5.01 | 45.25M | 170.00K | -16.59M | -15.98M | -1.9113 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Forecast Cut: What is Lisata Therapeutics Incs market positionInflation Watch & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Lisata Therapeutics Hits New 52-Week High of $5.06 - Markets Mojo
Lisata Therapeutics Q2 2025 Earnings Preview - MSN
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com Nigeria
Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - marketscreener.com
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lisata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Per Share Plus Potential $1.00 CVR in 2026 Merger Deal - Minichart
Market movers: Hims & Hers, Lisata Therapeutics, Live Nation Entertainment... - Proactive financial news
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Yahoo Finance
Lisata Therapeutics to Be Acquired by Kuva Labs - TipRanks
Lisata Therapeutics to Be Acquired by Kuva Labs in $5.00-Per-Share Tender Offer Plus $1.00 CVR - TradingView
Kuva Labs to acquire Lisata (Nasdaq: LSTA) for $5.00 cash plus CVR - Stock Titan
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs - Nasdaq
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs in $5.00 per Share Deal - GuruFocus
Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc. - TradingView
Lisata Therapeutics Announces Acquisition by Kuva Labs Inc. with $5.00 Cash Offer per Share - Quiver Quantitative
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire
Lisata Therapeutics enters into definitive agreement to be acquired by Kuva Labs, Inc. - marketscreener.com
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - TipRanks
Lisata Extends Kuva Tender Offer Term Sheet to March 7 as Acquisition Talks Continue - TradingView
Will Lisata Therapeutics Inc. stock go up in YEARJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - mfd.ru
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq
LSTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Why is Lisata Therapeutics Inc. stock going downAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
What is the long term forecast for Lisata Therapeutics Inc. stockJuly 2025 Decliners & Comprehensive Market Scan Insights - mfd.ru
Can Lisata Therapeutics Inc. keep up with sector leadersTrade Risk Summary & Free Accurate Trade Setup Notifications - mfd.ru
LSTA PE Ratio & Valuation, Is LSTA Overvalued - Intellectia AI
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Finansavisen
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):